Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00376)
Name
Lorcaserin
Synonyms    Click to Show/Hide the Synonyms of This API
Lorcaserin; 616202-92-7; (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; Belviq; UNII-637E494O0Z; (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 1H-3-Benzazepine, 8-chloro-2,3,4,5-tetrahydro-1-methyl-, (1R)-; CHEMBL360328; CHEBI:65353; Lorqess; 637E494O0Z; NCGC00182550-01; DSSTox_CID_28585; DSSTox_RID_82856; DSSTox_GSID_48659; Belvig; Lorcaserin [INN]; CAS-616202-92-7; HSDB 8128; (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine; SCHEMBL169382; GTPL2941; DTXSID3048659; ZINC6733300; Tox21_113018; AC-553; ANW-60436; BDBM50161646; AKOS006326204; Tox21_113018_1; AB52744; AM81248; CS-1232; DB04871; SB16626; NCGC00182550-02; HY-11093; AB0148401; W-5409; 202L927; Q340139
Clinical Status
Approved
Disease Indication Obesity ICD-11: 5B81 [1]
PubChem CID
11658860
Formula
C11H14ClN
Canonical SMILES
C[C@H]1CNCCC2=C1C=C(C=C2)Cl
InChI
1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1
InChIKey
XTTZERNUQAFMOF-QMMMGPOBSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=11658860"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 195.69 Topological Polar Surface Area 12
XlogP 2.7 Complexity 172
Heavy Atom Count 13 Rotatable Bond Count 0
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 1
Full List of Drug Formulations (DFMs) Containing This API
          Lorcaserin 20 mg tablet Click to Show/Hide the Full List of Formulation(s):          2 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c yellow no. 6; Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Silicon dioxide; Aluminum oxide; Cellulose, microcrystalline; Ethylcelluloses; Hypromellose 2208 (4000 mpa.s); Hypromellose 2910 (15 mpa.s); Polyethylene glycols; Polyvinyl alcohol, unspecified
                   Dosage Form 24 HR Extended Release Oral Tablet
                   Company Eisai
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sunset yellow FCF DIG Info Solute carrier SLCO2B1 (Ki = 68.4 uM) [2]
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c yellow no. 6; Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Silicon dioxide; Aluminum oxide; Cellulose, microcrystalline; Ethylcelluloses; Hypromellose 2208 (4000 mpa.s); Hypromellose 2910 (15 mpa.s); Polyethylene glycols; Polyvinyl alcohol, unspecified
                   Dosage Form 24 HR Extended Release Oral Tablet
                   Company Eisai
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sunset yellow FCF DIG Info Solute carrier SLCO2B1 (Ki = 68.4 uM) [2]
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Silicon dioxide DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
          Lorcaserin 10 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Croscarmellose sodium; Hydroxypropyl cellulose (80000 mw); Aluminum oxide; Cellulose, microcrystalline; Hypromellose 2208 (4000 mpa.s); Polyethylene glycols; Polyvinyl alcohol, unspecified
                   Dosage Form Oral Tablet
                   Company Eisai
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [5]
Hydroxypropyl cellulose DIG Info Mephenytoin 4-hydroxylase (EC50 = 89.5 uM) [6]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
          Lorcaserin Hydrochloride 10mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Silicified Microcrystalline Cellulose Nf; Hydroxypropyl Cellulose Nf; Croscarmellose Sodium Nf; Polyvinyl Alcohol Usp; Polyethylene Glycol Nf; Titanium Dioxide Usp; Talc Usp; Fd&C Blue 2/Indigo Carmine Aluminum Lake; And Magnesium Stearate Nf
                   Dosage Form Tablet
                   Company Eisai
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [5]
Hydroxypropyl cellulose DIG Info Mephenytoin 4-hydroxylase (EC50 = 89.5 uM) [6]
Polyvinyl alcohol DIG Info Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) [6]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
Polyethylene glycol 4000 DIG Info Albendazole monooxygenase (Inhibition ratio < 40 %) [7]
          Lorcaserin Hydrochloride 20mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Microcrystalline Cellulose Nf; Mannitol Usp; Hypromellose Usp; Ethylcellulose Dispersion Type B Nf; Colloidal Silicon Dioxide Nf; Polyvinyl Alcohol Usp; Polyethylene Glycol Nf; Titanium Dioxide Usp; Talc Usp; Fd&C Yellow 6/Sunset Yellow Fcf Aluminum Lake; Iron Oxide Yellow Nf; Iron Oxide Red Nf; Magnesium Stearate Nf
                   Dosage Form Tablet
                   Company Eisai
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [3]
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [6]
Polyvinyl alcohol DIG Info Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) [6]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Polyethylene glycol 4000 DIG Info Albendazole monooxygenase (Inhibition ratio < 40 %) [7]
References
1 FDA label for approved lorcaserin from the official website of the U.S. Food and Drug Administration.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.
4 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.
5 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
6 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
7 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.